AMRX vs KEYS · P/E 44, rev $2.79B vs P/E 57, rev $4.98B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Keysight Technologies Inc (KEYS) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Keysight Technologies Inc (KEYS) is a scientific & technical instruments company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported KEYS revenue for 2024-10-31 was $4.98B. Net income was $614.0M. Revenue was down 8.9% from 2023-10-31 to 2024-10-31. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
Not investment advice. Open the AMRX and KEYS stock pages for the full models.
Not investment advice.